| 0 (0%) | 12-26 21:19 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.44 | 1-year : | 7.91 |
| Resists | First : | 5.51 | Second : | 6.77 |
| Pivot price | 5.46 |
|||
| Supports | First : | 3.49 | Second : | 2.9 |
| MAs | MA(5) : | 4.27 |
MA(20) : | 5.49 |
| MA(100) : | 6.54 |
MA(250) : | 4.37 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 11.3 |
D(3) : | 13.7 |
| RSI | RSI(14): 31.7 |
|||
| 52-week | High : | 9.32 | Low : | 0.15 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AEZS ] has closed above bottom band by 13.1%. Bollinger Bands are 94.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.09 - 4.12 | 4.12 - 4.14 |
| Low: | 3.56 - 3.59 | 3.59 - 3.62 |
| Close: | 3.96 - 4.01 | 4.01 - 4.06 |
Wed, 07 Aug 2024
Aeterna Zentaris not so eternal after all as biopharma rebrands to become ‘COSCIENS Biopharma’ - Fierce Pharma
Tue, 06 Aug 2024
Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc. - Stock Titan
Fri, 17 May 2024
Aeterna Zentaris Announces Details Regarding Transaction with Ceapro - Yahoo Finance
Fri, 14 Jul 2023
Aeterna Zentaris updates progress of development pipeline - BioWorld MedTech
Thu, 06 Apr 2023
Aeterna (AEZS) Falls 5% on US Sales Halt of Growth Hormone Drug - Yahoo Finance
Tue, 26 Jul 2022
Gatwick Airport publishes Airport Economic Zone research - Passenger Terminal Today
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 1.2e+006 (%) |
| Held by Institutions | 1.3 (%) |
| Shares Short | 9 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.989e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -152 % |
| Return on Assets (ttm) | 750 % |
| Return on Equity (ttm) | -30 % |
| Qtrly Rev. Growth | 2.37e+006 % |
| Gross Profit (p.s.) | -44.16 |
| Sales Per Share | -36.16 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.12 |
| Price to Cash Flow | 0.84 |
| Dividend | 0 |
| Forward Dividend | 5270 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|